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Objective  To investigate the effi   cacy of ultrasonography (US)-guided injections in patients with low lumbar facet 
syndrome, compared with that in patients who received fl  uoroscopy (FS)-guided injections.
Method  Fifty-seven subjects with facet syndrome of the lumbar spine of the L4-5 and L5-S1 levels were randomly 
divided into two groups to receive intraarticular injections into the facet joint. One group received FS-guided 
facet joint injections and the other group received US-guided facet joint injections. Treatment eff  ectiveness was 
assessed using a visual analogue scale (VAS), physician’s and patient’s global assessment (PhyGA, PaGA), and the 
modifi  ed Oswestry Disability Index (MODI). All parameters were evaluated four times: before injections, and at a 
week, a month, and three months after injections. We also measured, in both groups, how long it took to complete 
the whole procedure.
Results  Each group showed signifi  cant improvement from the facet joint injections on the VAS, PhyGA, PaGA, 
and MODI (p<0.05). However at a week, a month, and three months after injections, no signifi  cant diff  erences 
were observed between the groups with regard to VAS, PhyGA, PaGA, and MODI (p>0.05). Statistically signifi  cant 
diff  erences in procedure time were observed between groups (FS: 248.7±6.5 sec; US: 263.4±5.9 sec; p=0.023).
Conclusion  US-guided injections in patients with lumbar facet syndrome are as eff  ective as FS-guided injections 
for pain relief and improving activities of daily living.
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INTRODUCTION
  Lumbar facet or zygapophysial joints are common 
sources of lumbar spinal pain.
1 In addition to causing 
localized spinal pain, facet joint pain may refer to 
adjacent structures. In particular, lumbar facet joints 
may refer pain to the back, buttocks, and proximal 
lower extremities.
2 “Facet syndrome” includes buttock 
pain, pseudoradicular-type pain in the posterior thigh 
or inguinal area, tenderness of paravertebral regions 
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corresponding to facet joints, and aggravation of pain 
from maneuvers that exert maximum irritation on the 
joints, or from transitional movements. Facet syndrome 
is diagnosed by clinical characteristics and by excluding 
other causes of lower back pain.
3
  Facet joint injections are commonly administered to 
alleviate back pain and/or to aid in determining whether 
the facet joint is a source of pain. Injections are usually 
administered under fl  uoroscopy (FS) guidance to ensure 
success and to avoid complications.
4 Some physicians 
also use computed tomography (CT) scanning for 
guidance, when available. However, these techniques 
include exposure to ionizing radiation for both the 
patient and the therapist, and can only be performed in 
specially equipped pain clinics.
5
  In contrast ultrasonography (US) is a portable, modera-
tely priced imaging modality which is not associated 
with radiation exposure. The current role of US-guided 
injections has recently been summarized
6: so far, US has 
been used for guidance with a broad variety of injections. 
  Galiano et al.
7 demonstrated that a US approach to the 
facet joint is feasible and has minimal risk, compared 
to CT-controlled injections. CT-guided injections are 
difficult to perform because of the large size of the 
equipment required and the high cost. Therefore, the 
purpose of this study is to investigate the effi   cacy of US-
guided injections in patients with facet syndrome of the 
low lumbar spine, compared with that in patients who 
received FS-guided injections.
MATERIALS AND METHODS
Subjects
  Subjects who visited our outpatient department 
with low-back pain were included in the study. Fifty-
nine patients diagnosed with facet syndrome of the 
lumbar spine were participants, and fi  fty-seven patients 
completed the entire study protocol.
  Patients were included if they (1) had pain associated 
with lumbar hyper-extension, lateral flexion, and 
tenderness on paravertebral regions corresponding to 
facet joints but normal fi  ndings on the straight leg raise 
test and neurologic examination, (2) had undergone 
a simple X-ray of their lumbar spine, and (3) were >18 
years old. Patients were excluded if they (1) had a local 
or systemic infection, (2) had an allergy to steroids or 
lidocaine, (3) had uncorrectable coagulopathy, or (4) 
were pregnant.
7 Patients were randomly assigned to one 
of two groups to receive intraarticular injections into the 
lumbar facet joint. One group received FS-guided facet 
joint injections, and the other group received US HD 11 
XE (Philips Medical System, Bothell, USA)-guided facet 
joint injections. Facet joint injections were limited to the 
L4-5 and L5-S1 levels.
Method
  FS-guided procedure: FS-guided facet joint injections 
were administered in a fl  uoroscopy room at a radiology 
center. Interventions were performed in a 45
o tilted 
state from the prone position with a pillow under the 
abdomen.
8 If the facet joint was clearly identifi  ed under 
FS, a spinal needle was advanced perpendicularly until 
bony contact was felt. All procedures were performed 
under sterile conditions.
8 Each facet joint (left L4-5, L5-
S1 or right L4-5, L5-S1 or bilateral L4-5 and L5-S1 levels 
according to symptoms) was infiltrated with a mixture 
containing 10 mg of triamcinolone and 2 ml of 1% 
lidocaine. 
  US-guided procedure: US-guided injections were 
performed by one expert. Patients were placed in a prone 
position. Posterior paravertebral parasagittal sonograms 
were obtained to indentify of the different spinal levels 
(Fig. 1). The spinous process and adjacent structures 
(lamina of the vertebral arch, facet joint, accessory 
process, and mamillary process) were delineated 
by transverse sonograms at the target level, and the 
midpoint of the facet joint space was established.
9 All 
procedures were performed under sterile conditions. If 
the joint was clearly or partially visible, a spinal needle 
Fig. 1. L4-L5 spinous processes demonstrated in a posterior 
paravertebral parasagittal sonogram using ultrasonography.Dong Hwan Yun, et al.
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was advanced under US guidance into the joint space 
of each lumbar facet joint. The needle was inserted 1-2 
cm laterally from the midline at the lateral end of the 
transducer and precisely positioned in the US plane at an 
angle of approximately 45
o with respect to the axial plane 
until the needle tip reached the target and bony contact 
was felt.
9 Th   is enabled visualization of the needle, which 
appeared as a bright line-shaped echo pattern on the 
transverse sonogram (Fig. 2). If the needle placement was 
correct, a mixture containing 10 mg of triamcinolone and 
2 ml of 1% lidocaine was administered intraarticularly 
(until resistance was encountered) and injected around 
the posterior facet joint capsule, in the same manner as 
for the FS-guided injections. 
  Outcome measures: For comparison of improvements 
between the two groups, the following outcome measures 
were selected and evaluated; before injections and at a 
week, a month, and three months after injections. Pain 
regarding the facet joints was assessed using a visual 
analogue scale (VAS), and activities of daily living (ADL) 
were assessed using physician’s global assessment 
(PhyGA) (subjective), patient’s global assessment (PaGA) 
(objective), and the modified Oswestry Disability Index 
(MODI). Each assessment was evaluated when patients 
visited our outpatient department or completed a 
telephone survey. Procedure time was recorded for both 
groups. Elapsed time was measured from the moment of 
placing the patient in the prone position. If all injections 
were performed, the elapsed time was stopped and 
recorded.
  Statistical analysis: SPSS (version 16.0 for Windows) 
was used to compare differences in outcome measures 
(SPSS Inc., Chicago, USA). For nonparametric variables, 
the Wilcoxon signed-rank test was used for pairwise 
multiple comparisons. The Mann-Whitney U test was 
used for multiple comparisons between the two groups. 
A p-value<0.05 was considered signifi  cant.
RESULTS
  Among the fifty-seven subjects, thirty-two subjects 
received FS-guided injections, and twenty-five subjects 
received US-guided injections. The demographic 
characteristics of the groups are shown in Table 1.
  No clinically relevant diff  erences in outcome measures 
were observed between the two groups at baseline. 
Both groups that received FS- and US-guided injections 
showed significant improvement on the VAS, PhyGA, 
PaGA, and MODI at a week (p<0.05), a month (p<0.05), 
and three months (p<0.05) after injections (Table 2). 
  However, no signifi  cant diff  erences in the VAS, PhyGA, 
PaGA, and MODI were observed between the groups at a 
week, a month, and three months after injections (Table 
2). Statistically signifi  cant diff  erences in procedure time 
were observed between the groups (FS: 248.7±6.5 sec; US: 
263.4±5.9 sec; p=0.023).
DISCUSSION
  Facet joint injections are preferentially performed as 
CT-controlled or FS-controlled interventions. But, most 
practitioners prefer FS-guided injections in clinics, rather 
than CT, as a guide for facet joint injections.
  Galiano et al.
9 recently described the US approach for 
Fig. 2. (A) Photograph showing 
the position of the ultrasonography 
transducer for examining the left 
L4-5 lumbar facet joint (B) Sonogram 
corresponding to the transducer 
position shown in (A). SP: Spinal 
process, MF: Medial facet, LF: Lateral 
facet, Big open arrow: Needle, Small 
open arrow: Joint space, Small closed 
arrow: Facet joint capsule.USG Injection of Facet Syndrome
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Table 1. Demographic Characteristics and Injections Levels of Subjects
Variables  Fluoroscopy (n=32) Ultrasonography (n=25)
Age (years) 55.0±9.3 (31-62) 58.3±8.9 (33-71)
Sex (male/female) 15/17 12/13
Body mass index 24.2±2.2 23.8±2.7
Time post-onset (month)   3.0±2.1   3.1±2.3
Levels
Bilateral L4-5, L5-S1 21 17
Bilateral L4-5   1   1
Bilateral L5-S1   0   0
Unilateral L4-5, L5-S1   8   4
Unilateral L4-5   1   2
Unilateral L5-S1   1   1
Values are mean±standard deviation
Table 2. Comparison of Pre- and Post-Injections Outcome Measures within Groups and between Groups
FS US FS vs. US
Mean±SD p-value Mean±SD p-value p-value
VAS
Pre-injections   5.90±1.06   6.00±1.12
1 wk after injections   2.59±0.98 0.000*
,†   2.68±1.03 0.000*
,† 0.782
1 mo after injections   2.50±0.95 0.000*
,‡   2.60±0.87 0.000*
,‡ 0.612
3 mo after injections   3.03±0.97 0.000*
,§   2.96±0.68 0.000*
,§ 0.953
PaGA 
Pre-injections   2.38±0.66   2.44±0.65
1 wk after injections   1.31±0.59   0.000*
,†   1.36±0.49 0.000*
,† 0.575
1 mo after injections   1.06±0.25 0.000*
,‡   1.08±0.28 0.000*
,‡ 0.933
3 mo after injections   1.44±0.50 0.000*
,§   1.32±0.48 0.000*
,§ 0.372
PhyGA 
Pre-injections   2.44±0.50   2.52±0.51
1 wk after injections   1.66±0.50 0.000*
,†   1.72±0.46 0.000*
,† 0.664
1 mo after injections   1.25±0.44 0.000*
,‡   1.24±0.44 0.000*
,‡ 0.791
3 mo after injections   1.59±0.50 0.000*
,§   1.36±0.49 0.000*
,§ 0.082
MODI
Pre-injections   22.13±10.17 24.04±9.93
1 wk after injections 12.91±6.27 0.000*
,† 14.08±5.96 0.000*
,† 0.424
1 mo after injections 12.81±5.92 0.000*
,‡ 13.52±5.59 0.000*
,‡ 0.615
3 mo after injections 14.63±5.92 0.000*
,§ 16.16±6.20 0.000*
,§ 0.259
Values are mean±standard deviation
FS: Fluoroscopy, US: Ultrasonography, VAS: Visual analogue scale, PaGA: Patient’s global assessment, PhyGA: 
Physician’s global assessment, MODI: Modifi  ed Oswestry Disability Index
*p<0.05, 
†pre-injections vs. 1 wk after injections, 
‡pre-injections vs. 1 mo after injections, 
§pre-injections vs. 3 mo after 
injectionsDong Hwan Yun, et al.
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administering lumbar facet joint injections. To simulate 
joint infiltration, on an embalmed cadaver, a spinal 
needle was advanced under US guidance into the space 
of each lumbar facet joint. Placement of the needle tip 
was verified by CT. Therefore, the described technique 
of a US-guided approach to the joint space of the lumbar 
facet joint articulation has been demonstrated to be 
feasible and accurate.
10 The fact that US-guided facet 
joint injections can be rapidly performed in clearly 
visible cases is not surprising. Because of the immediate 
availability of information on the feasibility of US imaging 
of target structures, once visualized, the needle can be 
advanced to the target structure in just a few seconds 
and under safe, real-time-controlled conditions. In this 
study, the needle placement was correct in almost all 
cases in which the target could be precisely identified 
and visualized. No additional roentgenological control 
is required, if the target structures are exact using US. 
Therefore, US-guided injections could be performed 
simply in an outpatient clinic. Additionally, US is not 
associated with radiation exposure. Potential biological 
effects of high X-ray doses have been reviewed, and 
deterministic and stochastic effects on skin, bone, 
parotid glands, and lung were discussed.
11 Kim et al.
12 
reported pigmentation on the fingernail and hand after 
repeated performance of FS-guided procedures.
12
  In our study, the FS-guided and US-guided injection 
groups showed significant benefit on the VAS, PhyGA, 
PaGA, and MODI at a week, a month, and three months 
after injections. We used the VAS as a pain scale, and 
PhyGA, PaGA, and MODI as an ADL scale. In a previous 
study, the benefits of injections were assessed only 
by VAS, and the follow-up period after injections was 
only six weeks.
7 We diversified the evaluation tool and 
expanded the follow-up period to three months. Other 
activities in daily life appeared to show improvement 
according to pain reduction. Th   erefore, the eff  ectiveness 
of facet joint injections for treating low-back pain 
corresponded with the results of earlier studies.
13 No 
significant differences in the VAS, PhyGA, PaGA, and 
MODI were observed between the groups. In this regard, 
US-guided facet joint injections were not inferior by 
comparison with FS-guided injections for pain relief and 
improvement of ADL.
  A signifi  cant reduction of procedure time was observed 
for the FS-guided facet joint injections (248.7±6.5 sec) 
and for US-guided injections (263.4±5.9 sec) when 
the level of injections was limited to both the L4-5 
and L5-S1 levels (FS: 21; US: 16). This procedure time 
was only from the time the patient was lying in the 
prone position to receive the injections. Therefore, 
this time did not include a preparatory period, such as 
entry into the procedure room and adjustments of the 
equipment before injections. Although the time for the 
FS-guided injections was shorter than that for the US-
guided injections, conducting the FS-guided injections 
required additional time because of the arrangement of 
injection reservations, movement to the radiology center, 
and a longer preparatory period, including adjusting 
fluoroscopic equipment. However, these are not 
cumbersome procedures. Th   erefore, the total US-guided 
procedure time may be shorter than that for FS-guided 
injections. No major complications, such as hematoma 
or infection, were observed.
  Th   e present study had some limitations, which included 
a small patient group. Another limitation was that the 
level of injections was limited to only the lower lumbar 
spine, at the L4-5 and L5-S1 levels. As the level of facet 
joint increased, the facet joint became vertical, so the 
joint could not be well visualized on US, compared with 
that of lower lumbar levels, such as L4-5 and L5-S1. 
Therefore, we could not apply a broader lumbar spine 
level. Additionally, we measured the time only at the 
L4-5 and L5-S1 levels. Finally, a long-term follow-up 
evaluation should be included.
CONCLUSION
  In conclusion, US-guided injections in patients with 
lumbar facet syndrome are as eff  ectiveness as FS-guided 
injections for pain relief and improvement of ADL. US 
guidance is a rapid and safe means of ensuring that 
injections are administered into facet joints. Th  erefore,  it 
might be easy to perform this procedure in the outpatient 
department. US-guided injections are a good treatment 
choice for facet syndrome of the low lumbar spine.
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